scorecardresearch
Tuesday, November 5, 2024
TopicBharat Biotech

Topic: Bharat Biotech

Early orders, more funds, swift payments — govt panel tips for boosting India’s vaccine supply

According to report by inter-ministerial panel, Bharat Biotech could double its production capacity soon while Serum Institute of India is still looking for ways to expand production.

Bharat Biotech’s Covaxin production could go up 7 times with help from Karnataka, Gujarat labs

Plan to increase Covaxin production being overseen by 6-member inter-ministerial panel appointed to augment vaccine manufacturing as Covid cases see a second wave in India.

Prioritise Covid vaccine supplies within India over exports, govt tells Serum & Bharat Biotech

Health ministry officials say there is no ban on exports but govt is expanding the vaccination drive for which India needs more vaccines for domestic consumption. 

Expert panel recommends Covaxin for emergency use, moves out of ‘clinical trial mode’

The recommendations were made after analysis of interim data of the phase-3 clinical trial of Bharat Biotech's Covaxin's showed the efficacy of the vaccine to be 80.6%.

Delhi HC asks Serum Institute, Bharat Biotech to reveal Covid vaccine manufacturing capacity

The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against Covid.

Covaxin shows 81% interim efficacy in preventing Covid, Bharat Biotech says

Bharat Biotech's phase-3 trial was conducted on 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities.

PM Modi taking Covid shot powerful example, will reduce vaccine hesitancy — Bharat Biotech

Bharat Biotech chairman and MD Krishna Ella also expressed gratitude to PM Modi for reposing trust in the indigenously developed Covaxin.

Top WHO official backs Covaxin, says evidence maybe limited but India has every right to approve

Covaxin is one of two vaccines being administered as part of India’s Covid vaccination drive. It was given conditional emergency-use nod in absence of complete Phase 3 trial data.

How Bharat Biotech & Covaxin got caught in a swirl of controversy

Minutes from Jan meetings showed that India’s drug regulatory agency insisted on seeing efficacy data for Covaxin, before approving it for a restricted use in 'clinical trial mode'.

17% Indians in 30-69 age group may not be able to take Covaxin as they’re on blood thinner

Covaxin is contraindicated for people who use blood thinners, while Covishield asks recipients to inform physician. But doctors say there’s no rationale.

On Camera

Trudeau is nursing snakes in his own backyard. Misguided Sikhs in Canada are losing the plot

By turning a blind eye to the snakes in his own backyard, Trudeau is setting the stage for a disaster of epic proportions for his country, his people, and the world at large.

Watch CutTheClutter: Flattening INR-USD rate, and debate on pros and cons of a ‘strong’ rupee

In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.

India carries out 1st patrol in Depsang since disengagement with China, to take things ‘slow’

While there are patrolling points (PP) 10, 11, 12, 12A and 13 in the Depsang Plains, the patrol in the region Monday was carried out to only one point as decided by India and China.

Xi wanted to teach India about imbalance of power. We should take a budgetary lesson from it

While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.